Ascentage Pharma Group International Balance Sheet Health
Financial Health criteria checks 4/6
Ascentage Pharma Group International has a total shareholder equity of CN¥70.6M and total debt of CN¥1.8B, which brings its debt-to-equity ratio to 2510.1%. Its total assets and total liabilities are CN¥2.5B and CN¥2.4B respectively.
Key information
2,510.1%
Debt to equity ratio
CN¥1.77b
Debt
Interest coverage ratio | n/a |
Cash | CN¥1.10b |
Equity | CN¥70.63m |
Total liabilities | CN¥2.43b |
Total assets | CN¥2.50b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 36X's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥934.2M).
Long Term Liabilities: 36X's short term assets (CN¥1.3B) do not cover its long term liabilities (CN¥1.5B).
Debt to Equity History and Analysis
Debt Level: 36X's net debt to equity ratio (952.2%) is considered high.
Reducing Debt: 36X had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 36X has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 36X has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 17.1% each year.